Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis : A systematic review and individual patient data meta-Analysis from the OA trial bank

Runhaar, Jos ; Rozendaal, Rianne M. ; van Middelkoop, Marienke ; Bijlsma, Hans J.W. ; Doherty, Michael ; Dziedzic, Krysia S. ; Lohmander, L. Stefan LU orcid ; McAlindon, Timothy E ; Zhang, Weiya LU and Bierma-Zeinstra, Sita M (2017) In Annals of the Rheumatic Diseases 76(11). p.1862-1869
Abstract

Objective To evaluate the effectiveness of oral glucosamine in subgroups of people with hip or knee osteoarthritis (OA) based on baseline pain severity, body mass index (BMI), sex, structural abnormalities and presence of inflammation using individual patient data. Methods After a systematic search of the literature and clinical trial registries, all randomised controlled trials (RCTs) evaluating the effect of any oral glucosamine substance in patients with clinically or radiographically defined hip or knee OA were contacted. As a minimum, pain, age, sex and BMI at baseline and pain as an outcome measure needed to be assessed. Results Of 21 eligible studies, six (n=1663) shared their trial data with the OA Trial Bank. Five trials (all... (More)

Objective To evaluate the effectiveness of oral glucosamine in subgroups of people with hip or knee osteoarthritis (OA) based on baseline pain severity, body mass index (BMI), sex, structural abnormalities and presence of inflammation using individual patient data. Methods After a systematic search of the literature and clinical trial registries, all randomised controlled trials (RCTs) evaluating the effect of any oral glucosamine substance in patients with clinically or radiographically defined hip or knee OA were contacted. As a minimum, pain, age, sex and BMI at baseline and pain as an outcome measure needed to be assessed. Results Of 21 eligible studies, six (n=1663) shared their trial data with the OA Trial Bank. Five trials (all independent of industry, n=1625) compared glucosamine with placebo, representing 55% of the total number of participants in all published placebo-controlled RCTs. Glucosamine was no better than placebo for pain or function at short (3 months) and long-Term (24 months) follow-up. Glucosamine was also no better than placebo among the predefined subgroups. Stratification for knee OA and type of glucosamine did not alter these results. Conclusions Although proposed and debated for several years, open trial data are not widely made available for studies of glucosamine for OA, especially those sponsored by industry. Currently, there is no good evidence to support the use of glucosamine for hip or knee OA and an absence of evidence to support specific consideration of glucosamine for any clinically relevant OA subgroup according to baseline pain severity, BMI, sex, structural abnormalities or presence of inflammation.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
glucosamine, individual patient data, meta-Analysis, osteoarthritis, subgroups
in
Annals of the Rheumatic Diseases
volume
76
issue
11
pages
8 pages
publisher
BMJ Publishing Group
external identifiers
  • scopus:85030973077
  • pmid:28754801
  • wos:000412506700019
ISSN
0003-4967
DOI
10.1136/annrheumdis-2017-211149
language
English
LU publication?
yes
id
2e2abbc8-f41e-4165-9a0c-35dcd49be397
date added to LUP
2017-10-30 09:25:52
date last changed
2024-06-11 05:11:15
@article{2e2abbc8-f41e-4165-9a0c-35dcd49be397,
  abstract     = {{<p>Objective To evaluate the effectiveness of oral glucosamine in subgroups of people with hip or knee osteoarthritis (OA) based on baseline pain severity, body mass index (BMI), sex, structural abnormalities and presence of inflammation using individual patient data. Methods After a systematic search of the literature and clinical trial registries, all randomised controlled trials (RCTs) evaluating the effect of any oral glucosamine substance in patients with clinically or radiographically defined hip or knee OA were contacted. As a minimum, pain, age, sex and BMI at baseline and pain as an outcome measure needed to be assessed. Results Of 21 eligible studies, six (n=1663) shared their trial data with the OA Trial Bank. Five trials (all independent of industry, n=1625) compared glucosamine with placebo, representing 55% of the total number of participants in all published placebo-controlled RCTs. Glucosamine was no better than placebo for pain or function at short (3 months) and long-Term (24 months) follow-up. Glucosamine was also no better than placebo among the predefined subgroups. Stratification for knee OA and type of glucosamine did not alter these results. Conclusions Although proposed and debated for several years, open trial data are not widely made available for studies of glucosamine for OA, especially those sponsored by industry. Currently, there is no good evidence to support the use of glucosamine for hip or knee OA and an absence of evidence to support specific consideration of glucosamine for any clinically relevant OA subgroup according to baseline pain severity, BMI, sex, structural abnormalities or presence of inflammation.</p>}},
  author       = {{Runhaar, Jos and Rozendaal, Rianne M. and van Middelkoop, Marienke and Bijlsma, Hans J.W. and Doherty, Michael and Dziedzic, Krysia S. and Lohmander, L. Stefan and McAlindon, Timothy E and Zhang, Weiya and Bierma-Zeinstra, Sita M}},
  issn         = {{0003-4967}},
  keywords     = {{glucosamine; individual patient data; meta-Analysis; osteoarthritis; subgroups}},
  language     = {{eng}},
  month        = {{11}},
  number       = {{11}},
  pages        = {{1862--1869}},
  publisher    = {{BMJ Publishing Group}},
  series       = {{Annals of the Rheumatic Diseases}},
  title        = {{Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis : A systematic review and individual patient data meta-Analysis from the OA trial bank}},
  url          = {{http://dx.doi.org/10.1136/annrheumdis-2017-211149}},
  doi          = {{10.1136/annrheumdis-2017-211149}},
  volume       = {{76}},
  year         = {{2017}},
}